• Johnathan H Goree, Stuart A Grant, David M Dickerson, Brian M Ilfeld, Yashar Eshraghi, Sandeep Vaid, Ali K Valimahomed, Jarna R Shah, G Lawson Smith, John J Finneran, Nirav N Shah, Maged N Guirguis, Maxim S Eckmann, Ajay B Antony, Brian J Ohlendorf, Mayank Gupta, John E Gilbert, Amorn Wongsarnpigoon, and Joseph W Boggs.
• Department of Anesthesiology, University of Arkansas for Medical Sciences, Little Rock, AR, USA. Electronic address: JHGoree@uams.edu.
• Neuromodulation. 2024 Jul 1; 27 (5): 847861847-861.

ObjectivesTotal knee arthroplasty (TKA) is an effective surgery for end-stage knee osteoarthritis, but chronic postoperative pain and reduced function affect up to 20% of patients who undergo such surgery. There are limited treatment options, but percutaneous peripheral nerve stimulation (PNS) is a promising nonopioid treatment option for chronic, persistent postoperative pain. The objective of the present study was to evaluate the effect of a 60-day percutaneous PNS treatment in a multicenter, randomized, double-blind, placebo-controlled trial for treating persistent postoperative pain after TKA.Materials And MethodsPatients with postoperative pain after knee replacement were screened for this postmarket, institutional review board-approved, prospectively registered (NCT04341948) trial. Subjects were randomized to receive either active PNS or placebo (sham) stimulation. Subjects and a designated evaluator were blinded to group assignments. Subjects in both groups underwent ultrasound-guided placement of percutaneous fine-wire coiled leads targeting the femoral and sciatic nerves on the leg with postoperative pain. Leads were indwelling for eight weeks, and the primary efficacy outcome compared the proportion of subjects in each group reporting ≥50% reduction in average pain relative to baseline during weeks five to eight. Functional outcomes (6-minute walk test; 6MWT and Western Ontario and McMaster Universities Osteoarthritis Index) and quality of life (Patient Global Impression of Change) also were evaluated at end of treatment (EOT).ResultsA greater proportion of subjects in the PNS groups (60%; 12/20) than in the placebo (sham) group (24%; 5/21) responded with ≥50% pain relief relative to baseline (p = 0.028) during the primary endpoint (weeks 5-8). Subjects in the PNS group also walked a significantly greater distance at EOT than did those in the placebo (sham) group (6MWT; +47% vs -9% change from baseline; p = 0.048, n = 18 vs n = 20 completed the test, respectively). Prospective follow-up to 12 months is ongoing.ConclusionsThis study provides evidence that percutaneous PNS decreases persistent pain, which leads to improved functional outcomes after TKA at EOT.Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved.

26 keywords...

hide…